Special Issue

Microbes and Medicine— Papers from the 2025 OBASM Meeting

Message from the Guest Editors

The 2025 annual meeting of the Ohio Branch of the American Society for Microbiology (OBASM) will be held April 4–5 at Otterbein University in Westerville, Ohio. The conference has been designed to provide an overview of all aspects of microbiology, with sessions designed for senior through student researchers. Sessions include talks focusing on medical microbiology and environmental microbiology, examining basic science and applications. Meeting participants are invited to contribute articles to a Special Issue on *Drugs and Drug Candidates*. Articles should fall within the scope of the journal, including, but not limited to, papers on

- Development of new drugs for infectious diseases;
- Studies of genes that could be potential targets for therapeutic agents;
- Microbiome modification:
- Strategies to overcome antimicrobial agent resistance;
- In vitro and in vivo model evaluation and efficacy testing.

Both review and research articles are sought. While authors do not need to have attended the meeting, the journal has generously waived the article processing fees for attendees of the 2025 OBASM meeting.

Guest Editors

Prof. Dr. Paul Hyman

Department of Biology and Toxicology, Ashland Univeristy, Ashland, OH 44805, USA

Dr. Jennifer A. Bennett

Department of Biology and Earth Science, Otterbein University, Westerville, OH, USA

Deadline for manuscript submissions

30 October 2025



Drugs and Drug Candidates

an Open Access Journal by MDPI



mdpi.com/si/230474

Drugs and Drug Candidates Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 ddc@mdpi.com

mdpi.com/journal/ ddc





Drugs and Drug Candidates

an Open Access Journal by MDPI





About the Journal

Message from the Editor-in-Chief

Drugs and Drug Candidates is an open access initiative of MDPI (Basel, Switzerland). Do you wish to share your knowledge on marketed or newly approved drugs for human or veterinary use? Do you wish to disseminate your recent results on the search for novel promising drug candidates? Our journal, animated by a young and dynamic team, is the ideal platform! Your submission, carefully followed by an academic editor, will be peerreviewed by experts in the field of the work and a first decision will be notified within no more than two weeks. Involved in drug design, drug synthesis, drug evaluation, or drug market, Drugs and Drug Candidates is of worthy recognition and value.

I look forward to handling your contributions in the very near future. Should you need any information, do not hesitate to contact us.

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde Formerly Head, Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.